Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor ...

A Phase II trial of Recce Pharmaceutical’s topical skin infection gel has ‘exceeded expectations’, with 93% of patients achieving the primary efficacy endpoint. The Australian company’s ...

James Graham, Chief Executive Officer of Recce Pharmaceuticals, took up his full entitlement, investing a further $102.7K into the Company, with Directors intending to take up approximately ...

A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in ...

Following the raise, Recce will have a pro-forma cash position of $16m. This excludes an R&D rebate expected from the ATO in Q4 2025 of ~$8.5m and a further $10m in anticipated non-dilutive ...

Recce Pharmaceuticals (ASX:RCE) has secured the first tranche of a $30 million debt facility to continue running skin infection trials and boost commercialisation efforts across the ASEAN region ...

Stockhead TV less than 2 min read June 6, 2025 - 6:50AM Stockhead Long Shortz: Recce Pharmaceuticals ...

Recce Pharmaceuticals Ltd’s recent Annual General Meeting saw all proposed resolutions passed, showcasing strong shareholder support. The company’s innovative pipeline of synthetic anti ...

Recce Pharmaceuticals Ltd (ASX:RCE) successfully passed a resolution via poll at their Special General Meeting, marking a significant step in their strategic initiatives. The company is known for ...

James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, "We are extremely encouraged by the feedback from the non-Data Safety Monitoring Board and the profile of R327G. The absence of ...